Hyperliquid Strategies Inc (PURR) Stock Price, Quote & News

Company Profile

Hyperliquid Strategies Inc. operates as a digital asset treasury company in the United States. It focuses on building, managing, and optimizing HYPE tokens, which are the native digital assets of the Hyperliquid Layer-1 blockchain. The company is headquartered in New York, New York.

Industry: Capital Markets

Sector: Financial Services

Phone: 212 883 4241

Website: www.hypestrat.xyz

Address:

477 Madison Avenue, 22nd Floor, New York, United States

SteveO98 Sep. 14 at 5:23 PM

$PURR gift below 12

0 · Reply

stonedbunny Sep. 14 at 3:21 PM

$PURR Only non ai trade I have

0 · Reply

MesserschmittBavaria Sep. 14 at 3:18 PM

$PURR $HYPE.X $SOL.X When the hype hits 90-100$ or Solana 115$ how much do you think Purr could be worth? I firmly believe it's between $16 and $20. Let's see buy, hold, and enjoy.😉

0 · Reply

MesserschmittBavaria Sep. 14 at 2:06 PM

$PURR buy hold buy and hold

0 · Reply

StockElementCorporation Sep. 14 at 1:35 PM

So far crypto names are showing strength. $HOOD , $BMNR , $PURR

1 · Reply

MesserschmittBavaria Sep. 14 at 1:28 PM

$PURR first rebound will gotcha 13$

0 · Reply

Amudo Sep. 14 at 12:07 PM

$PURR first purchase was at $11.40. What's a good entry point for my second purchase? $11? $10.60?

0 · Reply

MesserschmittBavaria Sep. 14 at 11:43 AM

$PURR $HYPE.X is in hammer

0 · Reply

Baazigar123 Sep. 14 at 10:48 AM

$PURR $8?

0 · Reply

PURRfect Sep. 14 at 2:59 AM

$PURR Here we go!!!!!!

1 · Reply

Hyperliquid Strategies rises 11.0%

2026-09-10T11:55:51.000Z - 4 days ago

Hyperliquid Strategies price target raised to $34.20 from $22.60 at Cantor Fitzgerald

Sep 9, 2026, 8:00 AM EDT - 5 days ago

REX Shares Launches T-REX 2X PURR (KATT) ETF

Aug 28, 2026, 8:15 AM EDT - 17 days ago

PURR stock price forecast as Hyperliquid's HYPE token hits a record high

2026-08-27T19:35:28.000Z - 17 days ago

Hyperliquid Strategies price target raised to $22.60 from $18.40 at Cantor Fitzgerald

2026-08-27T16:05:39.000Z - 18 days ago

Hyperliquid Strategies rises 19.8%

Aug 27, 2026, 8:00 AM EDT - 18 days ago

Hyperliquid Strategies Earnings Call Transcript: Q4 2026

Aug 27, 2026, 8:00 AM EDT - 18 days ago

Hyperliquid Strategies Earnings release: Q4 2026

Aug 27, 2026, 8:00 AM EDT - 18 days ago

Hyperliquid Strategies Slides: Q4 2026

Aug 27, 2026, 8:00 AM EDT - 18 days ago

Hyperliquid Strategies Annual report: Q4 2026

Aug 27, 2026, 7:15 AM EDT - 18 days ago

Hyperliquid Strategies Inc Reports Financial Results for the Fiscal Year Ended June 30, 2026

2026-08-19T23:00:17.000Z - 25 days ago

Trump suggests possibility of regulating Hyperliquid, CNBC reports

CBOE CME MIAX

Aug 19, 2026, 4:15 PM EDT - 25 days ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Fiscal Year Ended June 30, 2026

Jul 21, 2026, 8:00 AM EDT - 7 weeks ago

Hyperliquid Strategies Registration statement: Registration filing

Jul 8, 2026, 8:30 AM EDT - 2 months ago

Defiance Launches PUR: The First 2X Long PURR ETF

PUR

Jun 29, 2026, 4:15 PM EDT - 2 months ago

Hyperliquid Strategies Inc Added to the Russell 3000, Russell 2000 and S&P Global BMI Indices

Jun 25, 2026, 8:00 AM EDT - 2 months ago

Hyperliquid Strategies Registration statement: Registration filing

Jun 16, 2026, 9:00 AM EDT - 3 months ago

Hyperliquid Strategies Inc Relaunches Website with Expanded Analytics, HYPE Tokenomics and Insights Sections

Jun 16, 2026, 8:00 AM EDT - 3 months ago

Hyperliquid Strategies Registration statement: Registration filing

Jun 4, 2026, 5:46 PM EDT - 3 months ago

Hyperliquid Strategies CEO on why he thinks banks are undervaluing SpaceX's IPO

SPCX

May 22, 2026, 8:00 AM EDT - 3 months ago

Hyperliquid Strategies Registration statement: Registration filing

May 7, 2026, 5:00 PM EDT - 4 months ago

Hyperliquid Strategies Earnings Call Transcript: Q3 2026

May 7, 2026, 5:00 PM EDT - 4 months ago

Hyperliquid Strategies Slides: Q3 2026

May 7, 2026, 5:00 PM EDT - 4 months ago

Hyperliquid Strategies Quarterly report: Q3 2026

May 7, 2026, 5:00 PM EDT - 4 months ago

Hyperliquid Strategies Earnings release: Q3 2026

May 7, 2026, 4:15 PM EDT - 4 months ago

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended March 31, 2026

May 7, 2026, 4:15 PM EDT - 4 months ago

Hyperliquid Strategies and Unit Labs Announce Validator on Hyperliquid

Apr 28, 2026, 4:15 PM EDT - 4 months ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Fiscal Quarter Ended March 31, 2026

Mar 24, 2026, 4:15 PM EDT - 5 months ago

Hyperliquid Strategies Inc. Announces Milestone with Launch of Options Trading on PURR Common Stock

Feb 16, 2026, 7:00 AM EST - 7 months ago

Hyperliquid Strategies Slides: Corporate presentation

Feb 11, 2026, 8:00 AM EST - 7 months ago

Hyperliquid Strategies Earnings Call Transcript: Q2 2026

Feb 11, 2026, 8:00 AM EST - 7 months ago

Hyperliquid Strategies Quarterly report: Q2 2026

Feb 11, 2026, 8:00 AM EST - 7 months ago

Hyperliquid Strategies Earnings release: Q2 2026

Feb 11, 2026, 8:00 AM EST - 7 months ago

Hyperliquid Strategies Slides: Q2 2026

Feb 11, 2026, 6:45 AM EST - 7 months ago

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended December 31, 2025

Feb 5, 2026, 4:15 PM EST - 7 months ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Quarter Ended December 31, 2025

Dec 8, 2025, 9:20 AM EST - 9 months ago

Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program

Dec 3, 2025, 5:45 PM EST - 9 months ago

Ex-Barclays CEO unpacks Hyperliquid: ‘The FUTURE of finance'

Dec 2, 2025, 4:30 PM EST - 9 months ago

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Nov 18, 2025, 9:00 AM EST - 10 months ago

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

Nov 12, 2025, 7:00 AM EST - 10 months ago

Hyperliquid Strategies Slides: Investor presentation

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Hyperliquid Strategies Registration statement: Registration Filing

Oct 15, 2025, 10:03 AM EDT - 11 months ago

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

Sep 19, 2025, 9:00 AM EDT - 12 months ago

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Aug 11, 2025, 9:15 AM EDT - 1 year ago

Sonnet Releases Virtual Investor "What This Means" Segment

Aug 4, 2025, 8:40 AM EDT - 1 year ago

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Jul 14, 2025, 6:00 AM EDT - 1 year ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

May 1, 2025, 9:00 AM EDT - 1 year ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Apr 4, 2025, 9:00 AM EDT - 1 year ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Apr 1, 2025, 4:15 PM EDT - 1 year ago

Sonnet Announces Release of Corporate Update Video

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Mar 26, 2025, 9:05 AM EDT - 1 year ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Mar 19, 2025, 8:50 AM EDT - 1 year ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Mar 11, 2025, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 26, 2025, 9:00 AM EST - 1 year ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Feb 19, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Feb 18, 2025, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 13, 2025, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025, 8:00 AM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Jan 28, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 22, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 21, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Dec 23, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 17, 2024, 8:50 AM EST - 1 year ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 9, 2024, 3:42 PM EST - 1 year ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2024, 8:45 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Dec 4, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Nov 12, 2024, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Nov 6, 2024, 1:20 PM EST - 1 year ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 6, 2024, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

SteveO98 Sep. 14 at 5:23 PM

$PURR gift below 12

0 · Reply

stonedbunny Sep. 14 at 3:21 PM

$PURR Only non ai trade I have

0 · Reply

MesserschmittBavaria Sep. 14 at 3:18 PM

$PURR $HYPE.X $SOL.X When the hype hits 90-100$ or Solana 115$ how much do you think Purr could be worth? I firmly believe it's between $16 and $20. Let's see buy, hold, and enjoy.😉

0 · Reply

MesserschmittBavaria Sep. 14 at 2:06 PM

$PURR buy hold buy and hold

0 · Reply

StockElementCorporation Sep. 14 at 1:35 PM

So far crypto names are showing strength. $HOOD , $BMNR , $PURR

1 · Reply

MesserschmittBavaria Sep. 14 at 1:28 PM

$PURR first rebound will gotcha 13$

0 · Reply

Amudo Sep. 14 at 12:07 PM

$PURR first purchase was at $11.40. What's a good entry point for my second purchase? $11? $10.60?

0 · Reply

MesserschmittBavaria Sep. 14 at 11:43 AM

$PURR $HYPE.X is in hammer

0 · Reply

Baazigar123 Sep. 14 at 10:48 AM

$PURR $8?

0 · Reply

PURRfect Sep. 14 at 2:59 AM

$PURR Here we go!!!!!!

1 · Reply

NetflixUser Sep. 14 at 12:32 AM

$PURR told everyone to short this. Sorry bulls.

0 · Reply

LarryLink Sep. 14 at 12:25 AM

$PURR Going down. Still waiting for collapse below 10. Everyone is giddy about crypto but the democrats will not give Trump a victory. A market crash will give them the ammo they need to destroy him in the midterms. Trump cannot attack Iran before midterms. To win you need to have collateral damage, that means also innocent Iranian people dying. The democrats would use this attack as reason to get rid of crazy Trump. Its all a political game. The democrats know what needs to happen. Prepare for a market crash.

0 · Reply

DoubleETrader Sep. 13 at 5:17 PM

$PURR https://x.com/beliukh_/status/2099055089071653138?s=42

0 · Reply

DoubleETrader Sep. 12 at 2:01 AM

$PURR Mnav is a little high right now. Should be continuing on this down trend. Position size target is 50,000 shares.

1 · Reply

JP00 Sep. 12 at 12:25 AM

$PURR $5 incoming when clarity is not passed on Tuesday.

1 · Reply

KornieAwareness7 Sep. 11 at 10:16 PM

$BTC.X $SOL.X $ETH.X $PURR Facts

6 · Reply

Baazigar123 Sep. 11 at 9:36 PM

$PURR

1 · Reply

Mungman Sep. 11 at 9:08 PM

$PURR 2nd time I flipped this beauty in a week. Its has trading patterns.

0 · Reply

topstockalerts Sep. 11 at 8:45 PM

$PURR this just keeps pushing without much effort

0 · Reply

TheHypeBull Sep. 11 at 7:28 PM

$PURR Patience my bulls, keep accumulating in the chop. I think downside is $HYPE.X may go to $72-75, upside is $200+ on a longer time frame. Accumulation of shares these next few months will pay off as crypto enters a bull trend. Have a HYPE weekend 🚀

0 · Reply

Smouky Sep. 11 at 7:05 PM

$PURR common don't be shy

0 · Reply

NetflixUser Sep. 11 at 6:56 PM

$PURR $11.50 target hit!!! Idiot bulls. This is so overvalued. It was $6 a month ago LOL use those brains. Holding puts to $11.30

2 · Reply

Market Cap	2.30B
Revenue (ttm)	9.46M
Net Income (ttm)	305.54M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	3.43
Profit Margin	3,229.81%
Debt to Equity Ratio	0.00

Volume	6,966,288
Avg Vol	16,228,118
Day's Range	N/A - N/A
Shares Out	197.84M
Stochastic %K	34%
Beta	1.89
Analysts	Strong Sell
Price Target	$23.73